For Immediate Release


Representative: Sunao Manabe, Representative Director, President and COO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126

Daiichi Sankyo Launches New Generic Drugs through Its Daiichi Sankyo Espha Subsidiary

Tokyo, Japan (June 15, 2017) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that on June 16, 2017, its generics subsidiary, Daiichi Sankyo Espha Co., Ltd (hereinafter, Daiichi Sankyo Espha), will launch eleven new generic drugs with six new active ingredients, out of the seventeen new drugs and eight new active ingredients that have been announced through today’s official gazette.


Overview of Newly Released Products


1.       Product Names/Therapeutic Categories

Products launched on June 16 (Authorized Generic products marked with an asterisk)

Product name

Therapeutic category

Original brand name

*Telmisartan Tablets 20mg  “DSEP”

Biliary excretion sustained release AT1 receptor antagonist

Micardis Tablets


*Telmisartan Tablets 40mg  “DSEP”

*Telmisartan Tablets 80mg  “DSEP”

*Teramuro Combination Tablets AP “DSEP”

Biliary excretion sustained release AT1 receptor antagonist / Sustained release Ca antagonist combination

MicamloCombination Tablets AP/BP

*Teramuro Combination Tablets BP “DSEP”

*Telthia Combination Tablets AP “DSEP”

Biliary excretion sustained release AT1 receptor antagonist

/ Diuretic combination

MicombiCombination Tablets AP/BP

*Telthia Combination Tablets BP “DSEP”

Entecavir Tablets 0.5mg “DSEP”

Antiviral chemotherapeutic agent

Baraclude Tablets 0.5mg

Montelukast Chewable Tablets 5mg “DSEP”1

Leukotriene receptor antagonist/

Bronchial asthma treatment

Singulair Chewable Tablets 5mg

KIPRES Chewable Tablets 5mg

Montelukast Powder 4mg “DSEP” 1

SingulairPowder 4mg

KIPRES Powder 4mg

Folinate Tablets 25mg “DSEP”

Reduced folic acid formulation

Uzel Tablets 25mg

Leucovorin Tablets 25mg

1Montelukast Chewable Tablets 5mg “DSEP” and Montelukast Powder 4mg “DSEP” are new formulations of previously released active ingredients.


Daiichi Sankyo Espha is the only company to have listed the following six new generic drugs and two new active ingredients in the National Health Insurance reimbursement price list. Daiichi Sankyo Espha will prepare diligently and launch the products and related information in mid-September.


Products to be launched in mid-September (Authorized Generic products marked with an asterisk)

Product name

Therapeutic category

Original brand name

*Olmesartan OD Tablets 5mg “DSEP”

High affinity AT1 receptor antagonist

OlmetecOD Tablets


*Olmesartan OD Tablets 10mg “DSEP”

*Olmesartan OD Tablets 20mg “DSEP”

*Olmesartan OD Tablets 40mg “DSEP”

*Rosuvastatin Tablets 2.5mg “DSEP”

HMG-CoA reductase inhibitor

CrestorTablets 2.5mg/5mg

*Rosuvastatin Tablets 5mg “DSEP”


2.       Product Attributes

(1)          Innovative design of tablets


Double-sided printing

Information including product name and active ingredients are printed on both sides of the tablet using inkjet or stamp pad printing, as appropriate, making the tablets easy to identify.

Other innovations

The flavor and stability have been improved according to the individual characteristics of each formulation, in addition to which the shelf-lives of these products have been extended.



(2)          Innovative design of PTP sheets

Continuing formulation and labeling innovations reduce the burden on pharmacists seeking to avoid mistakes with drugs and prevent medical errors such as a patient taking the wrong medicine.


(A)  Original, easily recognizable symbols

PTP sheets with original symbols based on formulation and disease characteristics.

(B)   GS1 code for each tablet

A GS1 DataBar barcode is displayed on the back of the PTP sheet to reduce the burden on pharmacists seeking to avoid mistakes when dispensing.

GS1 DataBar Barcodes

GS1 codes are a global standard adopted in 2010. DataBar barcodes are a GS1 code type that enables per sheet management of product name, content, volume and number of tablets.

(C)  Pitch control (fixed position printing)

Facilitates identification of product name, active ingredient and the name “DSEP.”

(D)  Other innovations

Montelukast Powder uses a rounded, easy-to-open stick package.


(3)          Innovative Box Design

Some of the new products will be in “iPackage” boxes that make various types of information available for confirmation at the time of dispensing.

About Daiichi Sankyo Espha

Based on the spirit of the Daiichi Sankyo Group corporate mission* of supplying pharmaceuticals to address diverse medical needs, Daiichi Sankyo Espha provides innovative high value-added generic drugs characterized by ingenious formulations and labeling as well as authorized generic drugs, which are manufactured from the same substances and additives, with the same manufacturing methods, in the same plant as the original drugs. Daiichi Sankyo Espha strives to provide pharmaceuticals that offer users peace of mind by fulfilling the most important pharmaceutical criteria of quality, information, and stable supply while delivering the economic benefits of generic drugs.

*Daiichi Sankyo Group corporate mission: To contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals and through the provision of pharmaceuticals addressing diverse medical needs.


Daiichi Sankyo Espha Company Overview

Company name: Daiichi Sankyo Espha Co., Ltd.

Established: April 1, 2010

Business: Manufacture and sale of pharmaceuticals

Capital: 450 million yen

Representative: President Hiroto Yoshiwaka

Headquarters: 3-5-1, Nihonbashi, Honcho, Chuo-ku, Tokyo